Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in advanced pancreatic NET
NCT00363051Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of everolimus in Pancreatic neuroendocrine tumor (PanNET), sponsored by Novartis. Primary endpoint: Objective Response Rate (Stratum 1) at 3 months. Started Jun 2006; status: completed.
02
Drugs
everolimus
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT00363051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363051.